Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Nyhus

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 25, 2026
Ingrid Nyhus, Erik Kreyberg Normann
BMC Research Notes|November 26, 2022
TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myelomaErling Håland, Ingrid Nyhus Moen, Esten N Vandsemb, et al.
Oncotarget|October 22, 2021
TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalanErling Håland, Ingrid Nyhus Moen, Elias Veidal, et al.
Cell Death Discovery|February 20, 2021
Smac-mimetics reduce numbers and viability of human osteoclastsIngrid Nyhus Moen, Marita Westhrin, Erling Håland, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 25, 2026
Ingrid Nyhus, Erik Kreyberg Normann
BMC Research Notes|November 26, 2022
TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myelomaErling Håland, Ingrid Nyhus Moen, Esten N Vandsemb, et al.
Oncotarget|October 22, 2021
TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalanErling Håland, Ingrid Nyhus Moen, Elias Veidal, et al.
Cell Death Discovery|February 20, 2021
Smac-mimetics reduce numbers and viability of human osteoclastsIngrid Nyhus Moen, Marita Westhrin, Erling Håland, et al.
Pageof 1